A Benefit-Risk Assessment of Inhaled Long-Acting β2-Agonists in the Management of Obstructive Pulmonary Disease View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2004-08

AUTHORS

Milind P. Sovani, Christopher I. Whale, Anne. E. Tattersfield

ABSTRACT

The two inhaled long-acting β2-adrenoceptor agonists, salmeterol and formoterol, have been studied extensively since their introduction in the early 1990s. In this review we consider the evidence for their efficacy and safety in adults with asthma and chronic obstructive pulmonary disease (COPD), by reviewing long-term prospective studies in which these drugs have been compared with placebo or an alternative bronchodilator. We have also assessed safety, including data from postmarketing surveillance studies and case-control studies using large databases.In patients with asthma, salmeterol and formoterol increase lung function, reduce asthmatic symptoms and improve quality of life when compared with placebo. Both drugs protect against exercise-induced asthma, although some tolerance develops with regular use. Tolerance to the bronchodilator effects of formoterol has also been seen, although this is small and most of the beneficial effects are maintained long-term. Both drugs have been shown to reduce asthma exacerbations but only in studies in which most patients were taking an inhaled corticosteroid. Adding a long-acting β2-agonist provided better control than increasing the dose of inhaled corticosteroid in several studies. Long-acting β2-agonists also provide better asthma control than use of regular short-acting β2-agonists and theophylline. Their relative efficacy compared with leukotriene antagonists is uncertain as yet. Formoterol appears to be at least as safe and effective as a short-acting β2-agonist when used on an ‘as required’ basis.In patients with COPD, both salmeterol and formoterol offer improved lung function and reduced COPD symptoms compared with placebo, and quality of life has been improved in some studies. Some tolerance to the bronchodilating effect of salmeterol was seen in one study. Most studies have not found a significant reduction in exacerbations in COPD. Both drugs have provided greater benefit than ipratropium bromide or theophylline; there are limited data on tiotropium bromide.The long-acting β2-agonists cause predictable adverse effects including headache, tremor, palpitations, muscle cramps and a fall in serum potassium concentration. Salmeterol can also cause paradoxical bronchospasm. There is some evidence that serious adverse events including dysrhythmias and life-threatening asthma episodes can occur; however, the incidence of such events is very low but may be increased in patients not taking an inhaled corticosteroid.Salmeterol 50μg twice daily and formoterol 12μg twice daily are effective and safe in treating patients with asthma and COPD. Higher doses cause more adverse effects, although serious adverse events are rare. More... »

PAGES

689-715

Identifiers

URI

http://scigraph.springernature.com/pub.10.2165/00002018-200427100-00001

DOI

http://dx.doi.org/10.2165/00002018-200427100-00001

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1048743769

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/15350154


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Inhalation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adrenergic beta-2 Receptor Agonists", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adrenergic beta-Agonists", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Asthma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Delayed-Action Preparations", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lung Diseases, Obstructive", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Assessment", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Respiratory Medicine, City Hospital, Clinical Sciences Building, NG5 1PB, Nottingham, UK", 
          "id": "http://www.grid.ac/institutes/grid.412920.c", 
          "name": [
            "Division of Respiratory Medicine, City Hospital, Clinical Sciences Building, NG5 1PB, Nottingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sovani", 
        "givenName": "Milind P.", 
        "id": "sg:person.0726674327.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726674327.11"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Respiratory Medicine, City Hospital, Clinical Sciences Building, NG5 1PB, Nottingham, UK", 
          "id": "http://www.grid.ac/institutes/grid.412920.c", 
          "name": [
            "Division of Respiratory Medicine, City Hospital, Clinical Sciences Building, NG5 1PB, Nottingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Whale", 
        "givenName": "Christopher I.", 
        "id": "sg:person.0704760064.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0704760064.60"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Respiratory Medicine, City Hospital, Clinical Sciences Building, NG5 1PB, Nottingham, UK", 
          "id": "http://www.grid.ac/institutes/grid.412920.c", 
          "name": [
            "Division of Respiratory Medicine, City Hospital, Clinical Sciences Building, NG5 1PB, Nottingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tattersfield", 
        "givenName": "Anne. E.", 
        "id": "sg:person.013207152374.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013207152374.24"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.2165/00002018-200225030-00006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020065968", 
          "https://doi.org/10.2165/00002018-200225030-00006"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s001340050490", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041421538", 
          "https://doi.org/10.1007/s001340050490"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2004-08", 
    "datePublishedReg": "2004-08-01", 
    "description": "The two inhaled long-acting \u03b22-adrenoceptor agonists, salmeterol and formoterol, have been studied extensively since their introduction in the early 1990s. In this review we consider the evidence for their efficacy and safety in adults with asthma and chronic obstructive pulmonary disease (COPD), by reviewing long-term prospective studies in which these drugs have been compared with placebo or an alternative bronchodilator. We have also assessed safety, including data from postmarketing surveillance studies and case-control studies using large databases.In patients with asthma, salmeterol and formoterol increase lung function, reduce asthmatic symptoms and improve quality of life when compared with placebo. Both drugs protect against exercise-induced asthma, although some tolerance develops with regular use. Tolerance to the bronchodilator effects of formoterol has also been seen, although this is small and most of the beneficial effects are maintained long-term. Both drugs have been shown to reduce asthma exacerbations but only in studies in which most patients were taking an inhaled corticosteroid. Adding a long-acting \u03b22-agonist provided better control than increasing the dose of inhaled corticosteroid in several studies. Long-acting \u03b22-agonists also provide better asthma control than use of regular short-acting \u03b22-agonists and theophylline. Their relative efficacy compared with leukotriene antagonists is uncertain as yet. Formoterol appears to be at least as safe and effective as a short-acting \u03b22-agonist when used on an \u2018as required\u2019 basis.In patients with COPD, both salmeterol and formoterol offer improved lung function and reduced COPD symptoms compared with placebo, and quality of life has been improved in some studies. Some tolerance to the bronchodilating effect of salmeterol was seen in one study. Most studies have not found a significant reduction in exacerbations in COPD. Both drugs have provided greater benefit than ipratropium bromide or theophylline; there are limited data on tiotropium bromide.The long-acting \u03b22-agonists cause predictable adverse effects including headache, tremor, palpitations, muscle cramps and a fall in serum potassium concentration. Salmeterol can also cause paradoxical bronchospasm. There is some evidence that serious adverse events including dysrhythmias and life-threatening asthma episodes can occur; however, the incidence of such events is very low but may be increased in patients not taking an inhaled corticosteroid.Salmeterol 50\u03bcg twice daily and formoterol 12\u03bcg twice daily are effective and safe in treating patients with asthma and COPD. Higher doses cause more adverse effects, although serious adverse events are rare.", 
    "genre": "article", 
    "id": "sg:pub.10.2165/00002018-200427100-00001", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1096281", 
        "issn": [
          "0114-5916", 
          "1179-1942"
        ], 
        "name": "Drug Safety", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "10", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "27"
      }
    ], 
    "keywords": [
      "chronic obstructive pulmonary disease", 
      "serious adverse events", 
      "obstructive pulmonary disease", 
      "quality of life", 
      "adverse events", 
      "pulmonary disease", 
      "lung function", 
      "long-term prospective studies", 
      "effects of salmeterol", 
      "predictable adverse effects", 
      "adverse effects", 
      "exercise-induced asthma", 
      "better asthma control", 
      "serum potassium concentration", 
      "\u03b22-adrenoceptor agonists", 
      "case-control study", 
      "more adverse effects", 
      "benefit-risk assessment", 
      "alternative bronchodilators", 
      "paradoxical bronchospasm", 
      "salmeterol 50\u03bcg", 
      "formoterol 12\u03bcg", 
      "bronchodilator effect", 
      "asthma exacerbations", 
      "asthma control", 
      "asthmatic symptoms", 
      "most patients", 
      "muscle cramps", 
      "COPD symptoms", 
      "ipratropium bromide", 
      "tiotropium bromide", 
      "prospective study", 
      "leukotriene antagonists", 
      "asthma episodes", 
      "\u03b22 agonists", 
      "surveillance study", 
      "salmeterol", 
      "patients", 
      "asthma", 
      "formoterol", 
      "high doses", 
      "placebo", 
      "corticosteroids", 
      "beneficial effects", 
      "relative efficacy", 
      "regular use", 
      "drugs", 
      "exacerbation", 
      "potassium concentration", 
      "significant reduction", 
      "symptoms", 
      "disease", 
      "efficacy", 
      "most studies", 
      "great benefit", 
      "safety", 
      "bronchospasm", 
      "bronchodilators", 
      "palpitations", 
      "dysrhythmias", 
      "headache", 
      "cramps", 
      "agonists", 
      "antagonist", 
      "study", 
      "incidence", 
      "dose", 
      "doses", 
      "tremor", 
      "evidence", 
      "adults", 
      "effect", 
      "better control", 
      "episodes", 
      "events", 
      "control", 
      "tolerance", 
      "life", 
      "review", 
      "use", 
      "fall", 
      "assessment", 
      "function", 
      "management", 
      "data", 
      "quality", 
      "database", 
      "benefits", 
      "reduction", 
      "such events", 
      "concentration", 
      "Long", 
      "early 1990s", 
      "large database", 
      "introduction", 
      "bromide", 
      "basis"
    ], 
    "name": "A Benefit-Risk Assessment of Inhaled Long-Acting \u03b22-Agonists in the Management of Obstructive Pulmonary Disease", 
    "pagination": "689-715", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1048743769"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.2165/00002018-200427100-00001"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "15350154"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.2165/00002018-200427100-00001", 
      "https://app.dimensions.ai/details/publication/pub.1048743769"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:50", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_391.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.2165/00002018-200427100-00001"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00002018-200427100-00001'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00002018-200427100-00001'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00002018-200427100-00001'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00002018-200427100-00001'


 

This table displays all metadata directly associated to this object as RDF triples.

216 TRIPLES      21 PREDICATES      134 URIs      124 LITERALS      16 BLANK NODES

Subject Predicate Object
1 sg:pub.10.2165/00002018-200427100-00001 schema:about N06dd4fcb7ca24a7997e01944bc52ac8c
2 N0e2c24605d1d4e9c9ebe37f611c9d5af
3 N41cff9b5315a4e7a85ae42ca28118fec
4 N52587073a96b46efbe4b5742da318190
5 N8cdebbcb50ef4d6e9b88e685692fd84b
6 Nb3e3cc9b3ad94d7680d35aa2496dd5b6
7 Ncb2b5af665f64459a1529076901704f3
8 Nde3392acb3ad489bb4b4b636624dd888
9 Ndef906c0c16943f5a910c82b8728e692
10 anzsrc-for:11
11 anzsrc-for:1102
12 schema:author N8607da8a571345589b0427d7f271e7f5
13 schema:citation sg:pub.10.1007/s001340050490
14 sg:pub.10.2165/00002018-200225030-00006
15 schema:datePublished 2004-08
16 schema:datePublishedReg 2004-08-01
17 schema:description The two inhaled long-acting β2-adrenoceptor agonists, salmeterol and formoterol, have been studied extensively since their introduction in the early 1990s. In this review we consider the evidence for their efficacy and safety in adults with asthma and chronic obstructive pulmonary disease (COPD), by reviewing long-term prospective studies in which these drugs have been compared with placebo or an alternative bronchodilator. We have also assessed safety, including data from postmarketing surveillance studies and case-control studies using large databases.In patients with asthma, salmeterol and formoterol increase lung function, reduce asthmatic symptoms and improve quality of life when compared with placebo. Both drugs protect against exercise-induced asthma, although some tolerance develops with regular use. Tolerance to the bronchodilator effects of formoterol has also been seen, although this is small and most of the beneficial effects are maintained long-term. Both drugs have been shown to reduce asthma exacerbations but only in studies in which most patients were taking an inhaled corticosteroid. Adding a long-acting β2-agonist provided better control than increasing the dose of inhaled corticosteroid in several studies. Long-acting β2-agonists also provide better asthma control than use of regular short-acting β2-agonists and theophylline. Their relative efficacy compared with leukotriene antagonists is uncertain as yet. Formoterol appears to be at least as safe and effective as a short-acting β2-agonist when used on an ‘as required’ basis.In patients with COPD, both salmeterol and formoterol offer improved lung function and reduced COPD symptoms compared with placebo, and quality of life has been improved in some studies. Some tolerance to the bronchodilating effect of salmeterol was seen in one study. Most studies have not found a significant reduction in exacerbations in COPD. Both drugs have provided greater benefit than ipratropium bromide or theophylline; there are limited data on tiotropium bromide.The long-acting β2-agonists cause predictable adverse effects including headache, tremor, palpitations, muscle cramps and a fall in serum potassium concentration. Salmeterol can also cause paradoxical bronchospasm. There is some evidence that serious adverse events including dysrhythmias and life-threatening asthma episodes can occur; however, the incidence of such events is very low but may be increased in patients not taking an inhaled corticosteroid.Salmeterol 50μg twice daily and formoterol 12μg twice daily are effective and safe in treating patients with asthma and COPD. Higher doses cause more adverse effects, although serious adverse events are rare.
18 schema:genre article
19 schema:isAccessibleForFree false
20 schema:isPartOf N476a310227b242719219495957018612
21 Nbbb6df9e91df49ca940c2004e8b7c73b
22 sg:journal.1096281
23 schema:keywords COPD symptoms
24 Long
25 adults
26 adverse effects
27 adverse events
28 agonists
29 alternative bronchodilators
30 antagonist
31 assessment
32 asthma
33 asthma control
34 asthma episodes
35 asthma exacerbations
36 asthmatic symptoms
37 basis
38 beneficial effects
39 benefit-risk assessment
40 benefits
41 better asthma control
42 better control
43 bromide
44 bronchodilator effect
45 bronchodilators
46 bronchospasm
47 case-control study
48 chronic obstructive pulmonary disease
49 concentration
50 control
51 corticosteroids
52 cramps
53 data
54 database
55 disease
56 dose
57 doses
58 drugs
59 dysrhythmias
60 early 1990s
61 effect
62 effects of salmeterol
63 efficacy
64 episodes
65 events
66 evidence
67 exacerbation
68 exercise-induced asthma
69 fall
70 formoterol
71 formoterol 12μg
72 function
73 great benefit
74 headache
75 high doses
76 incidence
77 introduction
78 ipratropium bromide
79 large database
80 leukotriene antagonists
81 life
82 long-term prospective studies
83 lung function
84 management
85 more adverse effects
86 most patients
87 most studies
88 muscle cramps
89 obstructive pulmonary disease
90 palpitations
91 paradoxical bronchospasm
92 patients
93 placebo
94 potassium concentration
95 predictable adverse effects
96 prospective study
97 pulmonary disease
98 quality
99 quality of life
100 reduction
101 regular use
102 relative efficacy
103 review
104 safety
105 salmeterol
106 salmeterol 50μg
107 serious adverse events
108 serum potassium concentration
109 significant reduction
110 study
111 such events
112 surveillance study
113 symptoms
114 tiotropium bromide
115 tolerance
116 tremor
117 use
118 β2 agonists
119 β2-adrenoceptor agonists
120 schema:name A Benefit-Risk Assessment of Inhaled Long-Acting β2-Agonists in the Management of Obstructive Pulmonary Disease
121 schema:pagination 689-715
122 schema:productId N2cda530e82934e6e8d84f6a89fd98366
123 N4a6c4d61afa2413aac3cb5fd7552529f
124 Nb0c6ba3f134f49899e8c97714d16aa68
125 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048743769
126 https://doi.org/10.2165/00002018-200427100-00001
127 schema:sdDatePublished 2022-09-02T15:50
128 schema:sdLicense https://scigraph.springernature.com/explorer/license/
129 schema:sdPublisher Nbd62e961757541e0bf04a6d7b27deb49
130 schema:url https://doi.org/10.2165/00002018-200427100-00001
131 sgo:license sg:explorer/license/
132 sgo:sdDataset articles
133 rdf:type schema:ScholarlyArticle
134 N06dd4fcb7ca24a7997e01944bc52ac8c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Adrenergic beta-2 Receptor Agonists
136 rdf:type schema:DefinedTerm
137 N0d93a841a2824dab98a91b7d4b007ae3 rdf:first sg:person.0704760064.60
138 rdf:rest N9a57aba210204453867209b15f371c9d
139 N0e2c24605d1d4e9c9ebe37f611c9d5af schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Asthma
141 rdf:type schema:DefinedTerm
142 N2cda530e82934e6e8d84f6a89fd98366 schema:name pubmed_id
143 schema:value 15350154
144 rdf:type schema:PropertyValue
145 N41cff9b5315a4e7a85ae42ca28118fec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Risk Assessment
147 rdf:type schema:DefinedTerm
148 N476a310227b242719219495957018612 schema:volumeNumber 27
149 rdf:type schema:PublicationVolume
150 N4a6c4d61afa2413aac3cb5fd7552529f schema:name dimensions_id
151 schema:value pub.1048743769
152 rdf:type schema:PropertyValue
153 N52587073a96b46efbe4b5742da318190 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Humans
155 rdf:type schema:DefinedTerm
156 N8607da8a571345589b0427d7f271e7f5 rdf:first sg:person.0726674327.11
157 rdf:rest N0d93a841a2824dab98a91b7d4b007ae3
158 N8cdebbcb50ef4d6e9b88e685692fd84b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Adrenergic beta-Agonists
160 rdf:type schema:DefinedTerm
161 N9a57aba210204453867209b15f371c9d rdf:first sg:person.013207152374.24
162 rdf:rest rdf:nil
163 Nb0c6ba3f134f49899e8c97714d16aa68 schema:name doi
164 schema:value 10.2165/00002018-200427100-00001
165 rdf:type schema:PropertyValue
166 Nb3e3cc9b3ad94d7680d35aa2496dd5b6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Administration, Inhalation
168 rdf:type schema:DefinedTerm
169 Nbbb6df9e91df49ca940c2004e8b7c73b schema:issueNumber 10
170 rdf:type schema:PublicationIssue
171 Nbd62e961757541e0bf04a6d7b27deb49 schema:name Springer Nature - SN SciGraph project
172 rdf:type schema:Organization
173 Ncb2b5af665f64459a1529076901704f3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Lung Diseases, Obstructive
175 rdf:type schema:DefinedTerm
176 Nde3392acb3ad489bb4b4b636624dd888 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Delayed-Action Preparations
178 rdf:type schema:DefinedTerm
179 Ndef906c0c16943f5a910c82b8728e692 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Randomized Controlled Trials as Topic
181 rdf:type schema:DefinedTerm
182 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
183 schema:name Medical and Health Sciences
184 rdf:type schema:DefinedTerm
185 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
186 schema:name Cardiorespiratory Medicine and Haematology
187 rdf:type schema:DefinedTerm
188 sg:journal.1096281 schema:issn 0114-5916
189 1179-1942
190 schema:name Drug Safety
191 schema:publisher Springer Nature
192 rdf:type schema:Periodical
193 sg:person.013207152374.24 schema:affiliation grid-institutes:grid.412920.c
194 schema:familyName Tattersfield
195 schema:givenName Anne. E.
196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013207152374.24
197 rdf:type schema:Person
198 sg:person.0704760064.60 schema:affiliation grid-institutes:grid.412920.c
199 schema:familyName Whale
200 schema:givenName Christopher I.
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0704760064.60
202 rdf:type schema:Person
203 sg:person.0726674327.11 schema:affiliation grid-institutes:grid.412920.c
204 schema:familyName Sovani
205 schema:givenName Milind P.
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726674327.11
207 rdf:type schema:Person
208 sg:pub.10.1007/s001340050490 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041421538
209 https://doi.org/10.1007/s001340050490
210 rdf:type schema:CreativeWork
211 sg:pub.10.2165/00002018-200225030-00006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020065968
212 https://doi.org/10.2165/00002018-200225030-00006
213 rdf:type schema:CreativeWork
214 grid-institutes:grid.412920.c schema:alternateName Division of Respiratory Medicine, City Hospital, Clinical Sciences Building, NG5 1PB, Nottingham, UK
215 schema:name Division of Respiratory Medicine, City Hospital, Clinical Sciences Building, NG5 1PB, Nottingham, UK
216 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...